As a monotherapy, 7aaRGD does not reduce tumor growth, however, co-administration of the peptide with an anti-PD-1 antibody ultimately augments proinflammatory responses of myeloid cells and unleashes cytotoxic T cells activity, which leads to eradication of the tumors. This evidence concerns the gene PDCD1 and neoplasm.